title: The benchmark analysis of gastric, colorectal and rectal cancer pathways: toward establishing standardized clinical pathway in the cancer care.
abstract: Most clinical pathways in treating cancers in Japan are based on individual physician's personal experiences rather than on an empirical analysis of clinical data such as benchmark comparison with other hospitals. Therefore, these pathways are far from being standardized. By comparing detailed clinical data from five cancer centers, we have observed various differences among hospitals. By conducting benchmark analyses, providing detailed feedback to the participating hospitals and by repeating the benchmark a year later, we strive to develop more standardized clinical pathways for the treatment of cancers. The Cancer Quality Initiative was launched in 2007 by five cancer centers. Using diagnosis procedure combination data, the member hospitals benchmarked their pre-operative and post-operative length of stays, the duration of antibiotics administrations and the post-operative fasting duration for gastric, colon and rectal cancers. The benchmark was conducted by disclosing hospital identities and performed using 2007 and 2008 data. In the 2007 benchmark, substantial differences were shown among five hospitals in the treatment of gastric, colon and rectal cancers. After providing the 2007 results to the participating hospitals and organizing several brainstorming discussions, significant improvements were observed in the 2008 data study. The benchmark analysis of clinical data is extremely useful in promoting more standardized care and, thus in improving the quality of cancer treatment in Japan. By repeating the benchmark analyses, we can offer truly clinical evidence-based higher quality standardized cancer treatment to our patients.
authors.affiliation: Chiba Cancer Center, 666-2 Nitona-Cho, Chuo-Ku, Chiba City, Chiba, Japan. mryu@maple.ocn.ne.jp
authors.forename: Munemasa
authors.initials: M
authors.lastname: Ryu
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hamano
authors.forename: Akira
authors.initials: A
authors.lastname: Nakagawara
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shinoda
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miura
authors.forename: Isao
authors.initials: I
authors.lastname: Yoshida
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nemoto
authors.forename: Aki
authors.initials: A
authors.lastname: Yoshikawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D019985:Benchmarking; D002173:Cancer Care Facilities / Q000592:standards* / Q000639:trends; D003110:Colonic Neoplasms / Q000628:therapy*; D019091:Critical Pathways / Q000592:standards* / Q000639:trends; D006801:Humans; D007564:Japan; D010535:Laparoscopy; D007813:Laparotomy; D007902:Length of Stay; D019984:Quality Indicators, Health Care; D012004:Rectal Neoplasms / Q000628:therapy*; D013274:Stomach Neoplasms / Q000628:therapy*
chemical_list: D000900:Anti-Bacterial Agents